News

This clinical trial will study the safety and preliminary efficacy of DiaVacs’ novel dendritic cell therapy for treatment of type 1 diabetes in patients who are newly diagnosed.

AUGMENT is based on the company’s egg precursor cell (EggPC) technology and is being developed to improve egg quality and the success of in vitro fertilization (IVF). AUGMENT

BMN 250 is a new fusion of alpha-N-acetyglucosaminidase (NAGLU) with a peptide derived from insulin-like growth factor 2 (IGF2). The company has also started IND-enabling studies and intends

ILUVIEN, which provides a therapeutic benefit for up to 36 months, will now be be available in the NHS Scotland for the treatment of vision impairment related with

In 2012, Mogamulizumab was launched in Japan under the brand name POTELIGIO Injection 20 mg for the treatment of patients with relapsed or refractory CCR4-positive ATL. In July

During the trial, EYLEA 2mg dosed monthly and every two months (after 5 initial monthly injections) demonstrated an improvement from baseline in best corrected visual acuity (BCVA) at

The protocol was filed under the company’s existing IND for ORMD-0801 to include both type 1 and type 2 diabetes indications. The double-blind, randomized, placebo controlled, seven-day trial

The company has partnered with Ludwig Cancer Research over the last year to identify small molecule inhibitors of the enzyme that display nanomolar potency, good selectivity, favorable pharmacokinetics

With this new capability, Fluxion can now provide clinical sample procurement that includes fresh blood draws from a wide range of cancer indications and tumor subtype profiles, such